Ideas to Action:

Independent research for global prosperity

Views from the Center

CGD experts offer ideas and analysis to improve international development policy. Also check out our Global Health blog and US Development Policy blog.

 

An image of a doctor working on a laptop.

Rapid Priority Setting in Low- and Middle-Income Countries: The Potential of Adaptive Health Technology Assessments

Health budgets are limited and decision makers in all countries face very challenging decisions about which health interventions will be provided, and which will not. COVID has only added to this pressing priority setting problem. In this blog, we highlight key takeaways from our recent commentary in the BMJ Global Health, where we make the case for “adaptive health technology assessment,” or “aHTA.”

A doctor administering a COVID-19 test.

The Future of Development – What Will It Take to Achieve Universal Health?

Among the many disparities and inequities that COVID-19 has shone a light upon, the chasm in health outcomes between rich and poor countries is being particularly sharply highlighted. While Israel, the US, the UK, and a handful of high- and upper-middle income countries are charging forward with their vaccination programmes, many of the poorest are left behind—sometimes to rapidly soaring infection rates, as in India. Universal health—that is, a basic level of health and nutrition achieved globally—seems a distant prospect.

An image of Asian currency.

COVID-19 Financing and Development Pathways: Initial Reflections from the Asian Development Bank

COVID-19 and the economic crisis it unleashed have spurred unprecedented action from governments and international institutions. Multilateral development banks (MDBs) like the Asian Development Bank (ADB) swiftly committed resources to COVID-19 response and recovery efforts in 2020 and 2021, including a $20 billion countercyclical support facility and a $9 billion facility specifically for COVID-19 vaccine procurement and vaccination program implementation.

An image of the Covid-19 vaccine

How Can We Encourage COVID-19 Vaccine Developers to Expand Manufacturing Capacity?

Safe and efficacious vaccines are our best tools for defeating COVID-19. An unprecedented research and development effort has led to 12 vaccines with full or limited use emergency authorizations globally, but vaccinating everyone in the world as quickly as possible will require additional production capacity. Currently, there is not enough manufacturing capacity globally to accelerated immunization around the world in the next six months.

An image of a vaccine contract

Release COVID-19 Vaccine Contracts

Drugs created with billions in government support, bought almost exclusively by governments and international agencies are shrouded in secrecy: who is paying how much for delivery of what by when is a matter of guesswork and estimate.

Pages

Tags

Experts